Forward to the Past: The Case for Quantitative PET Imaging
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PET was developed in the 1970s as an in vivo method to measure regional pathophysiologic processes. In the 1990s the focus moved to the detection of local increases in uptake, first in the brain (activation studies) and later in oncology (finding metastases), with 18F-FDG emerging as a highly sensitive staging technique. This focus on sensitivity has overshadowed the other main characteristic of PET, its quantitative nature. In recent years there has been a shift. PET is now seen as a promising tool for drug development and precision medicine—that is, a method to monitor or even predict response to therapy. Quantification is essential for precision medicine, but many studies today use simplified semiquantitative methods without properly validating them. This review provides several examples illustrating that simplified methods may lead to less accurate or even misleading results. Simplification is important for routine clinical practice, but finding the optimal balance between accuracy and simplicity requires careful studies. It is argued that the use of simplified approaches without proper validation not only may waste time and resources but also may raise ethical questions, especially in drug development studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mapping human visual cortex with positron emission tomography
Fox, P. T., Mintun, M. A., Raichle, M. E., Miezin, F. M., Allman, J. M., & Van Essen, D. C. (1986) · Nature · doi:10.1038/323806a0 · Cited by 422 · cited 1×
“On the other hand, PET progressed into a more phenomenologic application, namely the detection of activated areas of CBF in the brain after a stimulus (22).”
BackgroundEttrup, A., Svarer, C., McMahon, B., da Cunha-Bang, S., Lehel, S., Møller, K., Dyssegaard, A., Ganz, M., Beliveau, V., Jørgensen, L. M., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.001 · Cited by 72
Enhancing Cardiac PET by Motion Correction Techniques
Rubeaux, M., Doris, M. K., Alessio, A., & Slomka, P. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0825-2 · Cited by 48 · cited 1×
“Although several methods have been developed to correct for patient motion (32), they require additional processing time.”
Method
Cited by
Cherry, S. R., Jones, T., Karp, J. S., Qi, J., Moses, W. W., & Badawi, R. D. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184028 · Cited by 763
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
“For a review on the value of full PET quantitation, see Lammertsma [94].”
BackgroundCan we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Metadata
- Authors
- Lammertsma, A. A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-05-18
- Volume
- 58
- Issue
- 7
- Pages
- 1019-1024
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2616489368
- Cited by
- 176
- References
- 3
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Forward to the Past: The Case for Quantitative PET Imaging. https://app.cochat.ai/papers/10.2967/jnumed.116.188029
- The paper
- Lammertsma, A. A. (2017). Forward to the Past: The Case for Quantitative PET Imaging. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.116.188029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.